Lack of association between lipoprotein(a) genetic variants and subsequent cardiovascular events in Chinese Han patients with coronary artery disease after percutaneous coronary intervention

Table 4 Univariate and multivariate analysis for 2-year MACE incidence

Univariate analysis	HR (95% CI)	P
Diabetes	1.54 (1.01-2.34)	0.047
Previous PCI	1.56 (0.98-2.49)	0.060
Number of vessels with lesions	1.32 (1,03-1.70)	0.030
β-blocker use	0.65 (0.42-1.02)	0.060
SBP	1.01 (1.01-1.02)	0.026
Lp(a) ≥ 30 mg/dL*	1.54 (1.05-2.27)	0.029
LVEF	0.98 (0.96-0.99)	<0.001
Multivariate analysis
Diabetes	1.50 (0.98-2.30)	0.061
Previous PCI	1.51 (0.95-2.41)	0.085
β-blocker use	0.62 (0.39-0.97)	0.035
SBP	1.02 (1.01-1.03)	<0.001
Lp(a) ≥ 30 mg/dL*	1.77 (1.19-2.63)	0.005
LVEF	0.97 (0.96-0.99)	<0.001

*Lp(a)<30 mg/dl was used for reference, Multivariate analysis was adjusted for diabetes, previous PCI, number of lesioned vessels, β-blocker use, SBP, LVEF and Lp(a) ≥ 30 mg/dL. Abbreviations: LVEF left ventricular ejection fraction, MACE major adverse cardiovascular event, SBP systolic blood pressure, PCI percutaneous coronary intervention.

ISSN: 1476-511X